A LOWER DOSAGE OF IMATINIB IS SUFFICIENT TO MAINTAIN UNDETECTABLE DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH LONG-TERM LOW-GRADE TOXICITY OF THE TREATMENT

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33154292" target="_blank" >RIV/61989592:15110/16:33154292 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.3109/10428194.2015.1056184" target="_blank" >http://dx.doi.org/10.3109/10428194.2015.1056184</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/10428194.2015.1056184" target="_blank" >10.3109/10428194.2015.1056184</a>

Result language
angličtina
Original language name
A LOWER DOSAGE OF IMATINIB IS SUFFICIENT TO MAINTAIN UNDETECTABLE DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH LONG-TERM LOW-GRADE TOXICITY OF THE TREATMENT
Original language description
The information about chronic myeloid leukemia (CML) patients with a deep molecular response of GREATER-THAN OR EQUAL TO 4.5 log reduction (MR4.5) in whom the dose of imatinib (IM) had to be reduced to relieve toxicity is insufficient. In 205 CML patients the dose of IM was reduced in 19 (31.2%) out of 61 patients with MR4.5. The patients (12 pretreated with interferon-alpha) achieved MR4.5 after an average of 27.7 months. The duration of MR4.5 before the reduction of the dose was 16-123 (mean = 56.7) months. After the IM reduction (200 mg daily to 400 mg twice weekly for 15-90 (mean = 48) months) MR4.5 or major molecular response (MMR) was maintained in 14 (73.7%) and 2 (10.5%) patients, respectively. Three patients who lost MMR (15.8%) after the discontinuation of IM regained MR4.5 after the reintroduction of a lower dose. A lower dosage of IM should be tested for the management of side effects in patients with MR4.5 in prospective studies.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)